This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Loteprednol ocular


Eye drops containing loteprednol etabonate

Drugs List

  • LOTEMAX 0.5% eye drops
  • loteprednol 0.5% eye drops
  • Therapeutic Indications


    Topical prophylaxis and treatment of inflammation after ocular surgery



    Instil one drop into the affected eye(s) four times daily beginning 24 hours after surgery and continuing throughout the post-operative period.

    The duration of treatment should not exceed 2 weeks.


    Instil one drop into the affected eye(s) four times daily beginning 24 hours after surgery and continuing throughout the post-operative period.

    The duration of treatment should not exceed 2 weeks.


    Children under 18 years
    History of herpes simplex keratitis
    Ocular infection
    Undiagnosed red eye

    Precautions and Warnings

    Wearing of contact lenses

    Exclude fungal invasion in cases of corneal ulceration
    May mask symptoms or signs of infections
    Advise patient blurred vision may affect ability to drive/operate machinery
    Contains benzalkonium chloride
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Check ocular lens frequently - risk of cataract formation
    Monitor intraocular pressure frequently - risk of steroid glaucoma
    May cause perforation of eye in disorders that thin the sclera or cornea
    Prolonged use may cause raised intraocular pressure
    Prolonged use may result in ocular infections
    Not recommended for use longer than 2 weeks
    Advise patient to avoid touching the eye/other surfaces with container tip
    Remove contact lenses before use and re-insert 15 minutes after use

    Pregnancy and Lactation


    Use loteprednol etabonate with caution in pregnancy.

    The manufacturer notes that the potential risk for humans is unknown and this medication should not be used in pregnancy unless clearly necessary.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Loteprednol etabonate is contraindicated in breastfeeding.

    It is not known whether loteprednol etabonate is excreted in human milk. Excretion in breast milk has not been investigated in animal studies.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Blurred vision (transient)
    Breast neoplasm
    Chest pain
    Conjunctival hyperaemia
    Conjunctival papillae
    Corneal disorders
    Dry eyes
    Dry skin
    Facial oedema
    Increased intra-ocular pressure
    Ocular burning
    Ocular discharge
    Ocular discomfort
    Ocular irritation
    Ocular pain
    Sensation of foreign body in eye
    Taste disturbances
    Urinary tract infections
    Weight gain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Accessed on 2.07.14].

    Summary of Product Characteristics: Lotemax 0.5% Eye Drops, Suspension, Bausch & Lomb UK Ltd, October 2012.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.